Citations

Clear

1707 citation(s) found for "He, Philip".

LATS1/2-CD38 Metabolic Rewiring Links Senescence to Intraplaque Thrombosis
Kotla, Sivareddy , Ko, Kyung Ae , Chen, Weiqing , Samanthapudi, Venkata Subrahman K, Hoang, Oanh, Mejia, Gilbert F. , Li, Shengyu , Lee, Hani , Zhang, Angie, Cho, Min Soon , Schadler, Keri L., Rivera, Luis Antonio, Samperio, Kay Carlene Tavares, Kim, Jung Hyun , Mendoza, Keila Carolina Ostos , Mariscal-Reyes, Karla N., Deswal, Anita, Fujiwara, Keigi , Koutroumpakis, Efstratios, Gi, Young Jin , Pathania, Rajneesh , Morrell, Craig N. , Lorenzi, Philip L. , Tan, Lin, Mahmud, Iqbal, Chini, Eduardo N., Herrmann, Joerg , Vasquez, Hernan G., Shen, Ying H. , Martin, James F. , Xu, Haodong, Le, Nhat‐Tu , Zhang, Aijun , Hoang, O.N. , Kim, Jung Hyun , Lee, Jonghae , Chen, Weiqing , Samanthapudi, Venkata Subrahmanya Kumar , Hoang, Oanh , Mejia, Gilbert , Li, Shengyu , Lee, Hani , Zhang, Aijun , Cho, Min Soon , Schadler, Keri , Rivera, Luis Antonio , Kim, Jung Hyun , Ostos-Mendoza, Keila C , Deswal, Anita M , Cooke, John P , Fujiwara, Keigi , Palaskas, Nicolas L , Koutroumpakis, Efstratios , Gi, Young Jin , Morrell, Craig , Lorenzi, Philip L , Madhmud, Iqbal , Hanssen, Nordin M J , Afshar-Kharghan, Vahid , Hamilton, Dale J , Yvan-Charvet, Laurent , Chini, Eduardo Nunes , Herrmann, Joerg , Shen, Ying H , Martin, James F , Seeley, Erin , Burks, Jared K , Brookes, Paul S , Wang, Guangyu , Le, Nhat-Tu , Abe, Jun-Ichi , Kotla, Sivareddy , Lee, Jonghae , Imanishi, Masaki , Cooke, John P. , Tan, Lin, Hamilton, Dale J. , Chini, Eduardo N. , Wang, Guangyu

Mayo Clinic

Circulation Research | May 27, 2026 | Volume: 139 | Issue: 2 | Pages: No page available

10.1161/circresaha.125.327427 | PMID 42200276 Get It

BACKGROUND: Atherothrombosis, which underlies most acute coronary syndromes and is driven by intraplaque thrombosis, preferentially occurs in regions of disturbed blood flow (d-flow). Although LATS1/2 (large tumor suppressor kinases 1 and 2) are known regulators of endothelial mechanotransduction, the mechanisms by which d-flow connects endothelial senescence, proliferation, and intraplaque thrombosis remain poorly understood. METHODS: We investigated endothelial cell (EC)-specific roles of Lats1/2 using inducible EC-specific knockout mice in a partial carotid ligation model. Spatial multiomics of human and mouse plaques was performed using imaging mass cytometry, COMET sequential immunofluorescence, and spatial metabolomics. RESULTS: Tamoxifen-induced deletion of both Lats1 and Lats2 (homozygous) in ECs caused fatal edema and increased vascular permeability. In contrast, Lats1 het ( ± ) / Lats2 homo ( −/−) -EC-specific knockout mice survived and developed spontaneous atherothrombotic plaques with neovascularization. Spatial proteomics revealed that LATS1/2 loss induced a senescence-associated stemness phenotype driven by CD38 upregulation. Spatial metabolomics showed sulfite and taurine accumulation, indicating SUOX (sulfite oxidase) deficiency. CD38 suppressed SUOX, demonstrated a switch into the reverse mode of mitochondrial complex V, increased succinate dehydrogenase activity, and promoted ATP consumption. Despite ATP depletion, glutamate metabolism and the citric acid cycle flux increased, sustaining EC proliferation under energetic stress. This senescence-associated stemness state promoted both proliferation and senescence, leading to fragile, leaky neovessels and intraplaque thrombotic lesions. Pharmacological CD38 inhibition attenuated these phenotypes. Similar EC states were observed in human plaques. CONCLUSIONS: Loss of Lats1/2 in ECs induces a CD38-associated senescence-associated stemness-like phenotype that promotes intraplaque thrombosis through mitochondrial metabolic reprogramming, including changes consistent with reverse-mode operation of mitochondrial complex V. These findings define a mechanistic link between disturbed flow, endothelial metabolic reprogramming, and intraplaque thrombosis and hemorrhage.
Variants in genes regulating thiamine metabolism in children in the Lao Thiamine study
Nunez, Kristin Cardiel , Smith, Taryn J. , Kounnavong, Sengchanh , Thacher, Tom D. , Fischer, Philip R. , Hess, Sonja Y. , Hess, Sonja Y , Smith, Taryn J , Kounnavong, Sengchanh , Thacher, Thomas D , Fischer, Philip R , Cardiel Nunez, Kristin E , Hess, Sonja Y.

Mayo Clinic

Paediatrics and International Child Health | May 27, 2026 | Volume: 46 | Issue: 1-2 | Pages: 34-39

10.1080/20469047.2026.2657620 | PMID 42192095 Get It

Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies
Morganti, Stefania , Kim, Se Eun , Jin, Qingchun , Cha, Jaeyoon , Zeigler, Jacqueline E, Newman, Alexandra Bili, Kirkner, Gregory J. , Snow, Craig , Zheng, Yue, Vincuilla, Julie, Parker, Tonia , Buehler, Ryan M. , Bychkovsky, Brittany L , Dibble, Kate E. , Sella, Tal , Ruddy, Kathryn J, Rosenberg, Shoshana M, Collins, Laura C. , Peppercorn, Jeffrey, Schapira, Lidia, Guzman-Arocho, Yaileen D, Come, Steven E. , Warner, Ellen, Poorvu, Philip D. , Lambertini, Matteo, Curigliano, G, Hughes, Melissa E. , Mittendorf, Elizabeth A, King, Tari A, Lin, Nancy U, Garber, Judy E, Tayob, Nabihah, Tolaney, S M, Partridge, Ann H, Zheng, Yue , Newman, Alexandra B , Zheng, Yue , Ruddy, Kathryn J , Peppercorn, Jeffrey M , Borges, Virginia F , Guzman-Arocho, Yaileen D , Come, Steven , Poorvu, Philip D , Lambertini, Matteo , Curigliano, Giuseppe , Mittendorf, EA , King, Tari A , Lin, Nancy U , Garber, J. E. , Tayob, Nabihah , Tolaney, Sara , Partridge, Ann H , Lynce, Filipa , Kirkner, Gregory , Snow, Craig , Vincuilla, Julie, Ruddy, Kathryn J. , Rosenberg, Shoshana M. , Peppercorn, Jeffrey , Schapira, Lidia , Borges, Virginia F. , Guzmán‐Arocho, Yaileen D. , Warner, Ellen , Lambertini, Matteo , Curigliano, Giuseppe , King, Tari A. , Lin, Nancy U. , Garber, Judy E. , Partridge, Ann H.

Mayo Clinic

JNCI Cancer Spectrum | May 23, 2026 | Volume: 10 | Issue: 4 | Pages: No page available

10.1093/jncics/pkag055 | PMID 42185079 Get It

Abstract Background Whether outcomes of germline BRCA1/2 (gBRCA1/2)-associated breast cancer differ compared with sporadic tumors is controversial. We explored the impact of gBRCA1/2 pathogenic variant (PV) status beyond established prognostic features. Methods We conducted 2 retrospective, matched cohort studies comparing gBRCA1/2 PV carriers and noncarriers with HER2-negative, stage I-III breast cancer (Clinical Outcomes Quality Database [COQD] cohort: 185 carriers, 555 noncarriers; Young Women’s Breast Cancer Study [YWS] cohort: 113 carriers, 226 noncarriers). Matching factors were age, stage, hormone receptor status, and year of diagnosis. Clinicopathological features, treatments, and survival outcomes were compared between carriers and noncarriers. Results Most patients in COQD had stage I-II disease (87.2%), and more carriers than noncarriers had genetic testing before diagnosis (33% vs 5.6%, P < .001). In YWS, 22.7% of patients had stage III tumors, and few were tested before diagnosis (14.8% of carriers vs 1.7% of noncarriers; P < .001). Carriers in COQD received chemotherapy more often than noncarriers (81.1 vs 67.0%, P < .001), including platinum (P = .010); the proportion was similar for carriers and noncarriers in YWS. After adjusting for chemotherapy, relapse-free survival was longer in carriers than noncarriers in COQD (adjusted hazard ratio = 0.48 [95% CI = 0.26 to 0.87], P = .016), and a favorable trend was observed for other survival outcomes in both cohorts. Triple-negative tumors appeared to drive the differences. Conclusions We observed a trend toward improved outcomes in gBRCA1/2 PV carriers compared with noncarriers. These findings suggest that carriers should not receive more aggressive treatment solely based on their germline mutation status. Prospective clinical trials in this population are warranted.
Streamlining Diagnosis of Bardet–Biedl Syndrome: New Diagnostic Algorithm With Updated Criteria
Pomeroy, Jeremy , Richards, Jesse , Kumar, S, Queen, Katie E., Zaritsky, Joshua, Cramer, Carl H. , Traboulsi, Elias I., Scruggs, Brittni A. , Davis, Erica E. , Keifer, Ekaterina , McGibbon, Emma, Ogden, Timothy, Graaf, B. de, Hymers, Tonia, FORSYTHE, ELIZABETH, Beales, Philip , Pomeroy, Jeremy J , Kumar, Seema , Cramer, Carl H , Scruggs, Brittni A , Davis, Erica E , Keifer, Ekaterina , Beales, Philip , Sweeney, Brooke , Zaritsky, Joshua J. , Traboulsi, Elias I. , Ogden, Timothy, Graaf, Bendert De

Mayo Clinic

American Journal of Medical Genetics Part A | May 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajmg.a.70199 | PMID 42175648 Get It

ABSTRACT Considerable advances have been made in our understanding of Bardet–Biedl syndrome (BBS), particularly in its core clinical features and molecular genetics, warranting an update to the existing diagnostic criteria framework. Using a rigorous, evidence‐based, and consensus‐driven process, a multidisciplinary group of international experts and patient‐led organizations developed an updated diagnostic algorithm. This algorithm provides practical, updated guidance for clinicians, including a pathway for accurately incorporating genetic findings into the diagnostic process. We recommend that a clinical diagnosis requires either 4 major criteria or 3 major and 2 minor criteria. Revised major criteria are retinal dystrophy, obesity (or overweight in individuals < 2 years old), congenital anomalies of the kidney and urinary tract or chronic kidney disease, hypogonadism/genital anomalies, neurodevelopmental/neurocognitive manifestations, and postaxial polydactyly. The diagnosis can also be established with a positive genetic testing result in patients exhibiting ≥ 1 major criterion, provided that genetic findings should be interpreted in the context of the patient's clinical presentation, age, family history, and overlap with related ciliopathies. These consensus criteria offer a simple algorithm incorporating updated definitions for major and minor criteria and genetic testing to support a timely and accurate diagnosis of patients with BBS, inform genetic counseling, and potentially facilitate earlier access to treatment. Trial Registration: CRIBBS Registry; ClinicalTrials.gov : NCT02329210
Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotype
Creamer, J. Philip , Ray, Suhita , Stewart, Sintra , Saliba, Antoine N. , Wu, Jieya , Huang, Frank Y. , Leppä, Aino‐Maija , Wang, Bofei , Abbas, Hussein A. , Abkowitz, Janis L. , Appelbaum, Jacob S, Becker, Pamela S., Jobanputra, Vaidehi , Fang, Min, Doulatov, Sergei, Saliba, Antoine N. , Saliba, Antoine N , Leppä, Aino-Maija , Wang, Bofei , Abbas, Hussein A , Kaufmann, Scott H , Becker, Pamela S , Swisher, Elizabeth M , Doulatov, Sergei , Saliba, Antoine N , Creamer, John Philip , Gülsüner, Süleyman , Appelbaum, Jacob , Kaufmann, Scott H. , Trumpp, Andreas , Fang, Min, Swisher, Elizabeth M.

Mayo Clinic

Blood Journal | May 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2025031996 | PMID 42166356 Get It

Clonal acquisition of multiple chromosomal abnormalities in hematopoietic stem and progenitor cells (HSPCs) is a hallmark of high-risk acute myeloid leukemias with complex karyotype (AML-CK). AML-CK is associated with TP53 mutations and chromosome 5q deletions (del5q); however, the drivers and clonal trajectories of aneuploid evolution in HSPCs remain unknown. We have developed a patient-derived induced pluripotent stem cell (iPSC) model in which preleukemic HSPCs clonally evolve to distinct, highly aneuploid states following transient mitotic inhibition. By tracking chromosome evolution at single cell resolution, we show that TP53-mutant HSPCs with del5q, but not TP53­ mutation alone, evolved complex chromosomal changes. Clonal evolution was marked by stepwise acquisition of numerical and structural chromosome changes seen in AML-CK patients, with individual abnormalities conferring fitness advantage. iPSC-derived aneuploid HSPCs and primary AML-CK patient samples exhibited a conserved gene expression signature marked by upregulation of PTEN, cohesins, and anti-apoptotic factor BCL2, indicative of a shared aneuploid cell state in HSPCs. Clinical BCL2 inhibitor venetoclax eradicated BCL2-dependent aneuploid clones, with resistant clones undergoing a lineage switch to upregulate alternative BCL2 factors. In summary, we demonstrate that mutant TP53 and del5q drive chromosome evolution marked by stepwise acquisition of individual abnormalities. Moreover, aneuploid HSPCs exhibit a shared gene expression state which confers unique targetable therapeutic vulnerabilities in AML-CK.
A case–control study of blood group antigen expression in Babesia microti infected patients in the United States
Jajosky, Ryan P. , Adjodha, Matthew, Tauscher, Craig D., Rupprecht, Jillian D., Dodge, Nicole R., Moldenhauer, Sheila K., Pritt, Bobbi S., Ruby, Kristen N. , Juskewitch, Justin E., Ruby, Kristen N , Jajosky, Ryan Philip , Berdan, Emma L. , Tauscher, Craig D. , Pritt, Bobbi S. , Juskewitch, Justin E.

Mayo Clinic

Transfusion | May 20, 2026 | Volume: 66 | Issue: 8 | Pages: 1587-1596

10.1111/trf.70272 | PMID 42157595 Get It

Abstract Background Babesia and Plasmodium are intraerythrocytic parasites that cause babesiosis and malaria, respectively. Significant associations between human blood group antigens and malaria are known; however, few studies have examined the relationship between blood group antigens and babesiosis. Study Design and Methods From June to August 2025, 100 Babesia polymerase chain reaction (PCR)− and 100 B. microti PCR+ human patient samples tested at a national reference laboratory underwent ABO and D phenotyping and red blood cell (RBC) genotyping of 37 antigens. Results The predicted phenotype of S‐s+ was found in 32% and 50% of Babesia − and B. microti + patients, respectively (χ 2 = 5.97, p = .015, odds ratio = 2.125, 95% confidence interval 1.18–3.78). Two B. microti + patients had the predicted phenotype of Fy(a‐b‐), meaning that Duffy is unlikely to be an essential invasion receptor. There were no statistically significant differences in ABO or D expression between the groups. Discussion Because multiple testing corrections were not applied to the statistical analyses, the S/s predicted phenotype results must be viewed as hypothesis‐generating. This may be the first study to link B. microti infection to human RBC S/s antigens, which are known to impact B. divergens and P. falciparum . Additional studies are needed to understand the impact of the babesiosis patient's blood type on B. microti infection and whether the transfusion of RBCs expressing specific antigens can impact the disease.
Use of impedance planimetry (325 catheter with 8-cm balloon) improves per-oral endoscopic myotomy outcomes in achalasia patients: a systematic review and a meta-analysis
Baig, Muhammad Usman , Gouda, Zane, Polavarappu, Abhishek Datta, Cricco-Lizza, Eliza, Solpari, Kate, Hanscom, Mark, Sampath, Kartik, Mahadev, SriHari , Al-Kandari, Asma, Aadam, A. Aziz , Gabr, Moamen, Haidry, Rehan, Elmunzer, Badih Joseph, Schnoll‐Sussman, Felice , Carr‐Locke, David L. , Katz, Philip O. , Pandolfino, John E. , Sharaiha, Reem Z. , Bhandari, Pradeep , Lahooti, Ali , Cricco‐Lizza, Eliza , Hanscom, Mark , Sampath, Kartik, Gabr, Moamen

Mayo Clinic

Diseases of the Esophagus | May 19, 2026 | Volume: 39 | Issue: 3 | Pages: No page available

10.1093/dote/doag054 | PMID 42296262 Get It

Summary Achalasia is a motility condition defined by failure of relaxation of the lower esophageal sphincter and loss of peristalsis in the distal esophagus. Per-oral endoscopic myotomy (POEM) is a technique to reduce lower esophageal sphincter pressure. We performed a systematic review and meta-analysis to assess the association between POEM and the clinical outcomes. We performed a systematic review and a meta-analysis (CRD420251052240). Literature search was done on PubMed and Embase (up to 8 June 2025). Original studies involving achalasia patients who underwent esophageal POEM with impedance planimetry using 8-cm balloon at 30 or 40 mL filling volumes with 325 catheter only (not the 322-N catheter) were included. The outcomes of interest were the clinical response groups (responders’ Eckardt score [ES] &lt; 3 and non-responders’ ES &gt; 3), reflux esophagitis, cross-sectional area (CSA), distensibility index (DI), and diameter. Nineteen studies with 1215 patients were included. The responders (ES &lt; 3) showed a statistically significantly greater increase in DI due to POEM (post-op minus pre-op) (mean difference [MD] = 1.92 mm2/mmHg [0.32, 3.53], P = 0.02) as well as a higher postoperative DI (MD = 1.87 mm2/mmHg [0.04, 3.70], P = 0.05) (40 mL). Reflux esophagitis group had statistically significantly higher CSA and diameter values (CSA MD = 15.68 mm2 [6.91, 24.24], P = 0.0005) (diameter MD = 0.96 mm [0.58, 1.33], P &lt; 0.00001) but no statistically significant difference for DI as compared to the non-reflux esophagitis group (DI MD = 0.19 mm2/mmHg [−0.51, 0.89], P = 0.59). In achalasia patients undergoing esophageal POEM, a greater interval increase in the DI as well as a higher post-procedural DI absolute value predicts a favorable clinical response. Higher postoperative CSA and diameter were linked to reflux esophagitis.
Pregnancy history, recency of childbirth, and outcomes in young women with early-stage breast cancer
Nader-Marta, Guilherme, Zheng, Yue, Rosenberg, Shoshana M, Dibble, Kate E. , Mayer, Erica L. , Poorvu, Philip D. , Ruddy, Kathryn J, Guzman-Arocho, Yaileen D, Collins, Laura C. , Peppercorn, Jeffrey, Schapira, Lidia, Tayob, Nabihah, Come, Steven E. , Warner, Ellen, Polyak, Kornelia, Partridge, Ann H. , Zheng, Yue , Marta, Guilherme Nader , Partridge, Ann H , Mayer, Erica L , Zheng, Yue , Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Guzmán‐Arocho, Yaileen D. , Peppercorn, Jeffrey , Schapira, Lidia , Valenza, Carmine , Borges, Virginia F. , Tayob, Nabihah , Warner, Ellen , Polyák, Kornélia , Winer, Eric P.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | May 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag152 | PMID 42152224 Get It

Abstract Background Breast cancer (BC) diagnosed during pregnancy or postpartum often presents with aggressive features, potentially influenced by hormonal, immunological, and tissue remodeling changes. Studies have suggested that postpartum BC may be associated with worse outcomes, though most evidence is retrospective and constrained by methodological limitations. This study evaluated associations between pregnancy history, recency of childbirth, and long-term outcomes in a prospective cohort of young patients with early-stage BC. Patients and Methods Patients aged ≤40 years with stage I–III BC enrolled in the Young Women’s Breast Cancer Study were categorized at diagnosis as nulligravid, nulliparous, pregnant, or parous (≤5 vs 5 to 10 years postpartum). Analyses were stratified by BC subtype (estrogen receptor-positive [ER+]/HER2−, HER2+, and triple-negative [TNBC]), with distant recurrence-free survival (DRFS) as the primary endpoint. Results Among 859 patients, 257 (29.9%) were nulligravid, 50 (5.8%) nulliparous, 37 (4.3%) pregnant, and 515 (60.0%) parous. Pregnant patients had proportionally more TNBC, nodal involvement, T3/T4, and grade 3 tumors. After 11.1 years median follow-up, pregnancy or postpartum status was not independently associated with DRFS in multivariable models adjusted for age, tumor characteristics, and treatment, with consistent findings across ER+/HER2−, HER2+, and TNBC subtypes. Sensitivity analyses, including further categorization of postpartum diagnoses (&lt;2 vs 2 to 5 years), yielded consistent results. Conclusions Pregnancy history and recency of childbirth were not independently associated with long-term DRFS. Despite more aggressive features at diagnosis, patients diagnosed during or after pregnancy had comparable outcomes after adjustment, suggesting no adverse prognostic impact. Clinical trial registration NCT01468246 (https://clinicaltrials.gov/study/NCT01468246? term=NCT01468246&rank=1).
Benefits of Electronic Symptom Monitoring During Cancer Treatment by Age, Sex, Race, and Education (Alliance AFT-39)
Deal, Allison M. , Sampathkumar, Yashasvini , Ginos, Brenda, Schrag, Deborah , Jansen, Jennifer , Stover, Angela M. , Carr, Philip M., Spears, Patricia A. , Jönsson, Mattias , Thanarajasingam, Gita , Rogak, Lauren , Cella, D, Given, Barbara, Zylla, Dylan M. , Weiss, Anna, Wolf, Anna P., Basch, Ethan , Blinder, V. S., Ginos, Brenda F, Mazza, Gina L , Schrag, Deborah , Jansen, Jennifer , Stover, Angela M , Spears, Patricia A , Jonsson, Mattias , Bennett, Antonia V , Thanarajasingam, Gita , Rogak, Lauren J , Reeve, Bryce B. , Snyder, Claire , Cella, David , Given, Barbara , Zylla, Dylan , Dueck, A. C. , Basch, Ethan , Blinder, Victoria S , Carr, Philip, Geoghegan, Cindy , Given, Barbara , Blinder, Victoria

Mayo Clinic

JCO Oncology Practice | May 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-26-00015 | PMID 42119041 Get It

PURPOSE Remote symptom monitoring using patient-reported outcomes (PROs) has been shown to improve symptom control and physical function among patients with advanced cancer. However, it is unclear whether these benefits are similar across demographic groups. This exploratory analysis of the PRO-TECT trial examined whether the effects of electronic symptom monitoring varied by race, age, sex, and educational attainment. METHODS PRO-TECT was a cluster randomized trial conducted across 52 US community oncology practices comparing weekly electronic symptom monitoring with usual care (UC). Adult patients with metastatic solid tumors receiving systemic therapy were enrolled (N = 1,191). Participants in the PRO arm completed weekly symptom surveys including the PRO-CTCAE, triggering alerts to the care team for severe or worsening symptoms. Patients chose whether to complete weekly PROs online or via telephone-based interactive voice response not requiring Internet access. Outcomes were measured using the European Organisation for Research and Treatment of Cancer QLQ-C30 symptom control and physical function scales. Subgroup analyses were performed by race (Black v White), age (<65 v ≥65 years), sex (male v female), and educational attainment (≤high school v >high school). RESULTS From baseline to 3 months, PRO participants showed greater improvements in symptom control (+2.37 v −0.20, P = .002) and physical function (+1.54 v −0.93, P = .02) versus UC. Benefits were most pronounced among younger, female, Black, and less educated participants. Black participants in the PRO arm were more likely to report that symptom reporting made them feel more in control of their care compared with White participants. CONCLUSION Electronic symptom monitoring improved quality-of-life outcomes overall, including among groups who have historically experienced higher symptom burden or barriers to communication. Remote PRO systems may represent an equitable strategy to enhance cancer care delivery.
Functional Outcomes in Bipolar Disorder: Cross-Cohort Analyses from the Global Bipolar Cohort
Yocum, *Anastasia K., Fullerton, *Janice M., Ashton, Melanie M., Overs, Browyn J., Diaz‐Byrd, Claudia , Albarracín-García, Lucía , Alda, Martin, Alexander, Nina , Altimus, Cara M. , Altınbaş, Kürşat, Andreassen, Ole A., Aubin, V. , Baca-García, Enrique, Baune, Bernhard T., Belzeaux, Raoul , Benavente-López, Sergio, Bengesser, Susanne A., Berk, Michael, Biernacka, Joanna, Blumberg, Hilary P., Burdick, Katherine E., Carpiniello, Bernardo, Chang, Chiao-Erh , Chen, Wen Yin, Clark, Scott R., Cleare, Anthony J., Contu, Martina , Dafnas, Konstantinos , Dannlowski, Udo, Dikeos, Dimitris, Dodd, Seetal, Dols, Annemieke, Dubertret, C, Etain, Bruno, Eyler, Lisa T., Fatjó‐Vilas, Mar , Ferentinos, Panagiotis, Ferguson, B. , Fernández, Ana L., Flinkenflügel, Kira, Forester, Brent P. , Fries, Gabriel R., Frye, Mark A., Fuentes-Claramonte, Paola, Gard, Sébastien, Gergel, Tania, Godin, O, Green, MJ, Haffen, E, Hahn, Tim, Havard, Alys, Jamalabadi, Hamidreza, Jansen, Andreas, Jones, I, Jones, Lisa A., Kelsoe, John R., Kircher, Tilo, Klaus, Federica, Kulkarni, Jayashri , Kupka, Ralph W., Leboyer, M, Lenger, Melanie , McElroy, Susan L., Machado-Vieira, Rodrigo, Manchia, Mirko, Martin, Nicolas G., Mata-Iturralde, Laura, Meinert, Susanne, Mitchell, Philip B., Mitra, Romita, Mohebbi, Mohammadreza , Mwangi, Benson, Nenadić, Igor, Nierenberg, Andrew A., Nunes, Abraham, Olié, E, O'Donovan, Clair, Orhan, Melis M., Passerieux, Christine, Perich, Tania, Peters, Amy T. , Petite, Joanne, Pham, Dániel , Pinna, M A, Platzer, Martina, Polosan, Mircea , Pomarol-Clotet, Edith, Porta-Casteràs, Daniel, Potter, Julia R., Quidé, Yann, Regeer, Eline J. , Rheenen, Tamsyn E. Van, Roberts, Gloria, Rodríguez-Cano, Elena, Rossell, Susan L., Sajatovic, Martha, Salvador, Raymond, Samalin, Ludovic, Sánchez-Alonso, Sergio, Sarró, Salvador , Schubert, Klaus O., Schwan, R, Scott, Katie , Shanahan, Megan, Soares, Jair C., Solé, Brisa, Stein, Dan J., Stein, Frederike, Strakowski, Stephen M., Straube, Benjamin, Strawbridge, Rebecca, Sullivan, Patrick F., Teutenberg, Lea, Thiel, Katharina , Thomas-Odenthal, Florian, Toma, Claudio, Usemann, Paula L., Vieta, Eduard, Vilella, Elisabet, Viswanath, Biju, Williams, Lana J., Wu, Mon-Ju, Yatham, Lakshmi N., Young, Allan H., McInnis, Melvin G., Almeida, Jorge, Bora, Emre, Cannon, Dara M., Chang, Yun-Hsuan, Chaumette, Boris, Chen, Jun, Ching, Christopher, Escamilla, Michael , Forstner, Andreas J., Goghari, Vina M. , He, Qin, Huang, Hailiang, Juruena, Mario F.; id_orcid 0000-0001-8558-3396, Kasyanov, Evgeny D., Koenig, B., Kovács, Zoltán , Kulkarni, Alok, Lee, Heon-Jeong, Lee, Jimmy, Liao, Duanping , LICHT, RASMUS W., Melle, Ingrid, Nicolini, Humberto, Okawa-Belizario, Gabriel, Prieto, Miguel L. , Raventós, Henriette , Ardestani, Seyed M. Samimi, Saunders, Erika F., Savitz, Jonathan, Schulze, Thomas G., Serretti, Alessandro, Simhandl, Christian , Straszek, Sune, SOUSA, RAFAEL TEIXEIRA DE , Thompson, Paul M., Tondo, Leonardo, Tourjman, S. Valérie, Zandi, Peter, Quidé, Yann , Overs, Bronwyn J. , Quidé, Yann , Sarró, Salvador , Yocum, Anastasia K. , Fullerton, Janice M. , Ashton, Melanie M. , Alda, Martin , Alonso-Lana, Sílvia , Altınbaş, Kürşat , Andreassen, Ole A , Antoniou, Anastasia , Baca‐García, Enrique , Baune, Bernhard T., López, Sergio Benavente , Berk, Michael , Beunders, Alexandra J.M. , Blumberg, Hilary P. , Brosch, Katharina , Burdick, Katherine E. , Callahan, Tiffany J , Cano, Marta , Cardoner, Narcı́s , Carpiniello, Bernardo , Chen, I‐Ming , Clark, Scott , Cleare, Anthony J. , Dalkner, Nina , Dannlowski, Udo , Dikeos, Dimitris, Dodd, Seetal , Dols, Annemiek , Dubertret, Caroline , Étain, Bruno , Eyler, Lisa T. , Fellendorf, Frederike T. , Flinkenflügel, Kira , Di Florio, Arianna , Fries, Gabriel R. , Frye, Mark A. , Fuentes‐Claramonte, Paola , Gergel, Tania , Godin, Ophélia , Gordon‐Smith, Katherine , Haffen, Emmanuel , Hahn, Tim , Hartmann, Simon , Havard, Alys , Hickie, Ian Bernard , Jamalabadi, Hamidreza , Jansen, Andreas , Kelsoe, John R , Kircher, Tilo , Klaus, Federica , Kuo, Po‐Hsiu , Kupka, Ralph , Lagerberg, Trine Vik , Leboyer, Marion , Lind, Penelope A. , McElroy, Susan L. , Machado‐Vieira, Rodrigo , Manchia, Mirko , Martínez‐Arán, Anabel , Medland, Sarah E. , Meinert, Susanne L. , Miklowitz, David J. , Millett, Caitlin E. , Mitchell, Philip B , Muntané, Gerard , Mwangi, Benson , Nenadić, Igor , Nierenberg, Andrew A. , Nurnberger, John I , Olié, Émilie , Orhan, Melis , Paribello, Pasquale , Passerieux, Christine , Perich, Tania , Pisanu, Claudia , Pomarol‐Clotet, Edith , Casteràs, Daniel Porta , Potter, Julia R, Reininghaus, Eva , Van Rheenen, Tamsyn , Ringin, Elysha , Ritter, Philipp , Roberts, Gloria, Rodríguez‐Cano, Elena , Rossell, Susan Lee , Sajatovic, Martha , Samalin, Ludovic , Scaini, Giselli , Schofield, Peter R. , Schouws, Sigfried N. T. M. , Schubert, Klaus Oliver , Schwan, Raymund , Shanahan, Megan, Siskind, Dan , Soares, Jair C. , Squassina, Alessio , Stein, Dan J. , Stein, Frederike , Strakowski, Stephen M. , Straube, Benjamin , Strawbridge, Rebecca , Stuart, Amanda L. , Teutenberg, Lea , Thomas‐Odenthal, Florian , Toma, Claudio , Torres, Ivan J. , Tsapekos, Dimosthenis , Ueland, Torill , Usemann, Paula L , Vieta, Eduard , Vilella, Elisabet , Viswanath, Biju , Winter, Alexandra , Wootton, Olivia , Wrobel, Anna L , Yatham, Lakshmi N. , Young, Allan H. , McInnis, Melvin G. , Bora, Emre , Cannon, Dara M. , Chaumette, Boris , Forstner, Andreas J. , Grigoroiu‐Serbânescu, Maria , He, Qin , Juruena, Mário F. , Kasyanov, Evgeny Dmitrievich , Koenig, Barbara, Lafer, Beny , Vernal, Ditte Lammers , Lee, Heon‐Jeong , McMahon, Francis J. , McQuillin, Andrew , Melle, Ingrid , Najand, Babak , Nicolini, Humberto , Belizário, Gabriel Okawa , Redlich, Ronny , Ardestani, Seyed Mehdi Samimi , Saunders, Erika F.H. , Savitz, Jonathan B. , Schulze, Thomas , Serretti, Alessandro , Σκώκου, Μαρία , Straszek, Sune Puggaard Vogt , Sousa, Rafael Teixeira de, Thompson, Paul M. , Tondo, Leonardo , Xiong, Ashley

Mayo Clinic

No container title available | May 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9390347/v1 Get It

Abstract Background The Global Bipolar Cohort (GBC) was established to identify existing bipolar disorder (BD) cohorts worldwide and foster collaborations focused on descriptive and analytic outcomes relevant to BD. A distributed analytic framework has been implemented to engage multiple sites without the need for central data pooling. This report describes the GBC endeavor and global functional impairment patterns. Cross-cohort comparisons of functional correlates are limited by heterogeneous measures and data-sharing constraints. Large, culturally diverse comparisons are needed to distinguish broadly reproducible correlates from cohort-specific effects. Participating sites completed a 28-item descriptive survey covering diagnostic methods, cognition, genetics, treatment, functioning, and follow-up strategies. We implemented a harmonized local logistic regression model of dichotomized functional outcome and shared summary statistics only. Results We identified 69 cohorts across five continents. Thirty-seven cohorts contributed functional outcome analyses from 17,130 participants. Outcome measures included clinician-rated disability scales and social indicators such as employment and marital status. The proportion classified with poor functioning ranged from 16% to 77% (mean 50%). In 32 of 37 cohorts, the overall regression model significantly explained variance in functioning. Current depressive symptoms were the most robust and reproducible correlate of poor functional outcome: they were assessed in 29 cohorts, significant in 22 (75.8%), ranked among the top three correlates in 22, and were the top-ranked correlates in 19. Associations between depressive burden and poor functioning were observed across clinician-rated disability scales and work or social indicators, and across geographically diverse cohorts. Comorbid substance use disorder and medication-related variables were associated with poorer functioning in subsets of cohorts, whereas sex, ancestry, bipolar subtype, psychosis history, and premorbid IQ showed weak or inconsistent associations. Cognitive measures, available in a minority of regression models, showed modest and non-uniform effects. Conclusions Across heterogeneous international cohorts, current depressive symptom burden emerged as the most consistent correlate of poor functioning in bipolar disorder. These findings replicate earlier multisite work at a larger scale, show that protocol-based distributed analyses can identify reproducible clinical signals without sharing individual-level data, and support prioritizing detection and treatment of depressive symptoms when aiming to improve real-world functioning. Future work should expand longitudinal harmonization and representation of under-studied populations.